Analgesic Ketamine for Battlefield Use
Dept of Defense · DEFENSE HEALTH AGENCY (DHA)
This notice is not accepting responses (deadline was Jan 12, 2026, 4:00 PM EST).
Page kept for research and related open opportunities below. For current work in this category, use the related notices or browse hubs.
- Response deadline
- Jan 12, 2026, 4:00 PM EST
- Posted
- Dec 16, 2025
- Solicitation
- HT9427-26-RFI-701
- Set-aside
- No Set aside used
- NAICS
- —
- PSC
- —
- Place of performance
- MD, USA
- Contracting office
- DEFENSE HEALTH AGENCY · FORT DETRICK · MD
- Source
- SAM.gov · updated Jul 5, 2026
Description
The purpose of this RFI is to address the OPMED WPAC PMO�s requirement for Tactical Combat Casualty Care (TCCC) solutions for acute severe pain from battlefield injuries. The OPMED WPAC PMO is conducting market research to determine the feasibility to collaborate with industry to develop, manufacturer, and receive U.S. Food and Drug Administration (FDA) approval of an analgesic ketamine product for procurement. All ketamine products for any route of administration will be considered, for example: autoinjectors, oral capsules, pumps, topical creams and patches, etc. OPMED WPAC PMO plans to release a request for proposals for the analgesic ketamine product in Fiscal Year 2026. Please see list of attachments for other instructions.
What similar awards have paid
Real federal awards already on the books in a similar lane — so you can size the opportunity, not guess. This is public history, not a bid price, cost estimate, or prediction that you will win.
Not enough similar awards to show a range yet
This notice is missing industry and product codes, so we cannot match past awards yet.
Intelligence only — not legal advice or a guarantee of award. Always verify requirements on the official SAM.gov notice. Past award amounts are public history, not a suggested bid or prediction. Notice ID fd09328814b04d5ab49e6869fa56df38.